Real‐World Treatment Escalation from Metformin Monotherapy in Youth‐Onset Type 2 Diabetes Mellitus: A Retrospective Cohort Study

In this retrospective cohort study using a longitudinal patient-level commercial insurance claims database, researchers sought to examine patterns and predictors of treatment escalation within five years of metformin monotherapy initiation for youth with type 2 diabetes in clinical practice.

Individuals with active enrollment from October 2000 to March 2020 who were diagnosed with incident type 2 diabetes between the ages of 10 and 18 were included in the study.

Cox proportional hazards regression was used to assess potential predictors of treatment escalation, including age, gender, race/ethnicity, comorbidities, complications, and metformin adherence (medication possession ratio ≥ 0.8).

The cohort involved 829 (66% female; median age at diagnosis 15 years; 19% Hispanic, 17% Black) patients, with a median 2.9‐year follow‐up after starting metformin.

Treatment escalation was positively associated with age at diagnosis, medication adherence, Hispanic ethnicity, and diabetes‐related complications. Treatment escalation for pediatric type 2 diabetes varies with age in clinical practice.

Non-insulin antihyperglycemics are used off-label, most commonly among older adolescents.

Masters of Pediatrics™ (MoP) is dedicated to the advancement of healthcare technologies and education serving as the academic home for child health professionals. Masters of Pediatrics offers continuing medical education, activities, and training through its advanced education entity Metabolic Medical Institute (MMI).
A division of Tarsus Medical owned by Tarsus Group

+1 (888) 555-1212

Copyright © 2022, A4M. All trademarks, registered or unregistered, are the property of their respective owners.